A carregar...
Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment. This retrospective cohort included patients hospitalized for a major bleed that result...
Na minha lista:
| Publicado no: | Clin Appl Thromb Hemost |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7019392/ https://ncbi.nlm.nih.gov/pubmed/31876159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029619896619 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|